Literature DB >> 17957468

Neuropsychological aspects of liver disease and its treatment.

R E O'Carroll1.   

Abstract

Liver disease can lead to serious impairment in cognitive functioning, through the development of a condition known as hepatic encephalopathy (HE). While gross impairment is clinically obvious, milder variants of the condition may escape detection at bedside examination and yet may have a significant impact on day-to-day activities. In this brief review article, the neuropsychology of liver disease is examined, focusing on nature, aetiology and significance. The possible contributory role of endogenous benzodiazepines in HE is described, as is the evidence regarding the effect of benzodiazepine antagonism on cognitive functioning in HE. The functional localisation of HE is briefly reviewed, as is the use of neuropsychological measures to evaluate treatment efficacy, e.g. following shunt procedures or liver transplantation. Finally, living donor liver transplantation is described, and the case is made for rigorous longitudinal neuropsychological evaluation of potential donors and recipients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17957468     DOI: 10.1007/s11064-007-9522-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  53 in total

1.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

2.  Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy.

Authors:  C L Yen; Y F Liaw
Journal:  Hepatogastroenterology       Date:  1990-06

3.  Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.

Authors:  A Watanabe; T Tuchida; Y Yata; Y Kuwabara
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

4.  Health-related quality of life after liver transplantation.

Authors:  A Hellgren; B Berglund; U Gunnarsson; K Hansson; U Norberg; L Bäckman
Journal:  Liver Transpl Surg       Date:  1998-05

5.  Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study.

Authors:  J W Moore; A A Dunk; J R Crawford; H Deans; J A Besson; G De Lacey; T S Sinclair; N A Mowat; P W Brunt
Journal:  J Hepatol       Date:  1989-11       Impact factor: 25.083

6.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

7.  Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.

Authors:  H Schomerus; W Hamster; H Blunck; U Reinhard; K Mayer; W Dölle
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

Review 8.  Benzodiazepine receptor antagonists for hepatic encephalopathy.

Authors:  B Als-Nielsen; L L Gluud; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 10.  Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy.

Authors:  R F Butterworth; L Spahr; S Fontaine; G P Layrargues
Journal:  Metab Brain Dis       Date:  1995-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.